Home > G. Tumoral pathology > Molecular pathology of tumors > Genetic anomalies > Cancer cytogenetics > Tumoral translocations > t(6;9)(p23;q34)
t(6;9)(p23;q34)
Monday 2 January 2012
Pathology
DEK-NUP214 (CAN-DEK) fusion gene
- The t(6;9)(p23;q34) associated DEK/CAN (CAN-DEK) fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation. (20827285)
Acute myelogenous leukemia (AML) with chromosomal translocation t(6;9)(p23;q34) is a rare disease with poor prognosis and distinct clinical and morphologic features.
- t(6;9) results in a chimeric fusion gene between DEK (6p23) and CAN/NUP214 (9q34).
- t(6;9) is most commonly associated with AML-FAB-M2 and is considered by some researchers to be a separate disease entity because of its distinct clinical and morphologic features and poor prognostic implication.
- Distinct morphologic features of this entity include marrow basophilia and myelodysplasia, and immunophenotypically, the blast cells are positive for CD9, CD13, CD33, and HLA-DR; are usually positive for CD45 and CD38; and may be positive for CD15, CD34, and terminal deoxynucleotidyl transferase.
References
The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation. Oancea C, Rüster B, Henschler R, Puccetti E, Ruthardt M. Leukemia. 2010 Nov;24(11):1910-9. PMID: 20827285
